Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled trial

J Clin Pharm Ther. 1998 Apr;23(2):155-9. doi: 10.1046/j.1365-2710.1998.00156.x.

Abstract

Objective: There is growing interest in investigating noradrenergic functions in obsessive-compulsive disorder (OCD) because some antidepressants with strong effects on serotonin reuptake blockade fail to relieve obsessive-compulsive symptoms. We undertook a trial to investigate whether the combination of clomipramine with nortriptyline was more effective than clomipramine alone.

Method: Thirty patients who met the DSM-IV criteria for OCD completed the study. Patients were allocated in a random fashion, 15 each to clomipramine 150 mg/ day plus nortriptyline 50 mg/day and clomipramine 150 mg/day plus placebo.

Results: Although both protocols significantly decreased the scores of the Yale-Brown obsessive-compulsive scale over the trial period, the combination of clomipramine and nortriptyline showed a significant superiority over clomipramine alone in the treatment of OCD.

Conclusion: As this study indicates, a rapid onset of action is one of the advantages of this combination. This study supports further investigation of the noradrenergic-serotonergic hypothesis in OCD.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adrenergic Uptake Inhibitors / therapeutic use*
  • Adult
  • Clomipramine / therapeutic use*
  • Double-Blind Method
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Humans
  • Male
  • Nortriptyline / therapeutic use*
  • Obsessive-Compulsive Disorder / drug therapy*
  • Placebos
  • Selective Serotonin Reuptake Inhibitors / therapeutic use*

Substances

  • Adrenergic Uptake Inhibitors
  • Placebos
  • Serotonin Uptake Inhibitors
  • Nortriptyline
  • Clomipramine